ROBBINSVILLE, N.J., March 12 /PRNewswire-FirstCall/ -- NexMed, Inc., a developer of innovative treatments based on its proprietary drug delivery system, today announced that the Department of Health has approved Befar® for sale and distribution in Hong Kong. Befar® is the Chinese trademark of Alprox-TD®, the Company's proprietary cream treatment for erectile dysfunction (``ED''). The product launch of Befar® in Hong Kong is scheduled to take place during the second quarter of 2002.
Dr. Y. Joseph Mo, president and chief executive officer of NexMed, commented, ``We are very excited about the approval and impending launch of Befar® in Hong Kong.'' Dr. Mo further added, ``We continue to pursue partnership opportunities for Alprox-TD® in the U.S., Europe and other international markets.''
Befar® will be manufactured and marketed in Hong Kong by Vergemont International Limited, NexMed's Asian licensee, and NexMed will receive royalty payments and payments for manufacturing supplies from Vergemont. Befar® has been on the market in China since July 2001. In November 2001, Vergemont filed a New Drug Application with the Health Sciences Authority for approval to market Befar® in Singapore.
Alprox-TD®/Befar® incorporates alprostadil, a drug well recognized for treating ED, with the NexACT® transdermal delivery technology. The product is pre-filled and packaged in NexMed's patented unit-dose dispenser, which is designed to provide an added convenience for patients. The disposable dispenser delivers a controlled dose of cream directly onto the tip (meatus) of the penis thereby reducing dosing errors and waste.
In the U.S., NexMed is conducting its Phase 3 clinical development programs for Alprox-TD®. The multi-center trials will enroll up to 2,500 patients with mild to severe ED. NexMed is also completing a Phase 2 multi-center take home study with its Femprox® topical treatment for female sexual arousal disorder (``FSAD'').
About NexMed, Inc.
NexMed, Inc., is a pharmaceutical company with a product development pipeline of innovative topical treatments based on the NexACT® acute transdermal delivery technology which include the Alprox-TD® and Femprox® cream for treating ED and FSAD, respectively. NexMed is also developing Viratrol®, a hand-held treatment device for herpes simplex lesions.
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to successful completion of clinical development programs, regulatory review and approval, product development and acceptance, manufacturing, competition, and/or other factors, some of which are outside the control of the Company.
SOURCE: NexMed, Inc.
For additional information, visit Nexmed: http://www.nexmedasia.com/product/new.htm